PLX — Protalix Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00
- $84.01m
- $80.63m
- $65.49m
- 22
- 79
- 56
- 51
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 54.7 | 62.9 | 38.4 | 47.6 | 65.5 |
Cost of Revenue | |||||
Gross Profit | 43.8 | 52 | 22 | 28 | 42.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 65.4 | 60.2 | 58.8 | 60.7 | 55 |
Operating Profit | -10.7 | 2.71 | -20.5 | -13 | 10.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -18.3 | -6.52 | -27.6 | -14.4 | 8.57 |
Provision for Income Taxes | |||||
Net Income After Taxes | -18.3 | -6.52 | -27.6 | -14.9 | 8.31 |
Net Income Before Extraordinary Items | |||||
Net Income | -18.3 | -6.52 | -27.6 | -14.9 | 8.31 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18.3 | -6.52 | -27.6 | -14.9 | 8.31 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.23 | -0.224 | -0.625 | -0.308 | 0.101 |